Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling

Area of Science:

• Oncology
• Genetics
• Genomics

Background:

• Anaplastic thyroid cancer (ATC) is a rare, highly aggressive malignancy with a poor prognosis.
• The comprehensive genetic underpinnings of ATC remain incompletely understood.
• There is a critical need for identifying novel therapeutic targets in ATC.

Purpose of the Study:

• To comprehensively analyze the genetic landscape of anaplastic thyroid cancer.
• To identify copy number alterations, gene fusions, and somatic mutations in ATC.
• To explore potential therapeutic targets based on genetic findings.

Main Methods:

• Whole exome sequencing and RNA-sequencing were performed on fourteen ATC cases.
• Analysis included delineation of copy number changes, fusion gene events, and somatic mutations.
• Mutational signatures were analyzed to understand underlying genomic processes.

Main Results:

• High frequency of genomic amplifications observed, including CCNE1 (29%) and CDK6 (9%), which are potential targets for CDK inhibition.
• TWIST1 amplification (9%) identified as another potentially targetable lesion.
• Frequent mutations included TP53 (55%), TERT promoter (36%), and ATM (27%).
• Mutational signatures implicated aging, DNA repair defects, AID/APOBEC activity, and tobacco exposure.

Conclusions:

• A significant proportion of ATCs (36%) harbor genetic alterations amenable to novel therapeutic strategies.
• Findings provide new insights into ATC tumorigenesis.
• Identified genetic events offer potential for developing targeted therapies for this aggressive cancer.